Dr Reddys Laboratories Ltd (DRREDDY) Share Price

Dr. Reddy's Laboratories is among India’s leading pharmaceutical companies. The company is primarily known for manufacturing active pharmaceutical ingredients (APIs). Dr. Reddy's Laboratories’ head office is located in Hyderabad, Andhra Pradesh. Dr. Reddy's Laboratories was established by Dr. Anji Reddy in 1984. In the same year, the company commenced operations at its first facility at Jeedimetla, Hyderabad. In 1985, Dr. Reddy's Laboratories began building its first API manufacturing facility. 1986 was the year when Dr. Reddy's Laboratories went public. In the same year, the company began exporting API Methyldopa. In 1987, Dr. Reddy's Laboratories received approval from the US Food and Drugs Administration to manufacture the painkiller, API ibuprofen. In the 1990s, the company expanded to more foreign markets such as Russia. It also expanded its portfolio and began manufacturing new products such as Omeprazole. 1993 was the year when Dr. Reddy’s Research Foundation was set up. In 1998, Dr. Reddy's Laboratories launched its Biologics business. The company’s shares were listed on the New York Stock Exchange in 2001. A year later, the firm made its first international acquisition. It purchased UK-based entities BMS Laboratories Limited and Meridian Healthcare. 2003 was a significant year for Dr. Reddy's Laboratories as it launched its first generic drug - Ibuprofen under its US label. In 2004, the company completed the acquisition of Trigenesis Therapeutics Inc., a US-based company. 2005 was the year when the company launched India’s first medicinal treatment for diabetic foot ulcers. Five years later, Dr. Reddy's Laboratories acquired the US penicillin facility and products of GlaxoSmithKline. 2016 was important for the company as it ventured into the Over the Counter (OTC) segment after acquiring six OTC brands from US-based Ducere Pharma. Three years later in 2019, the company entered the nutrition business by launching the diabetes nutrition drink Celevida. During the height of the COVID-19 pandemic, Dr. Reddy's Laboratories collaborated with many international entities to help fight the disease. In 2021, the company worked with Defence Research and Development Organisation (DRDO) to develop 2-DG (Deoxy-D-Glucose) for the treatment of COVID. As of March 2022, Dr. Reddy's Laboratories has a presence in over 60 countries. The company’s workforce comprises of over 24,000 employees from 48 different nationalities, as of March 2022. 
 
Products and services  

Dr. Reddy's Laboratories is a leading manufacturer and marketer of several APIs. APIs are the key components in the manufacture of pharmaceutical products. In FY22 alone, the company launched 157 new products. Apart from APIs, the company also produces branded generics for various therapeutic uses. Dr. Reddy's Laboratories also produces generic drugs such as Lenalidomide Capsules. Under the company’s Biologics business, it produces, develops and markets biosimilar products for oncology and immunology. The company also runs an OTC business which covers areas like pain management, dermatology, gastrointestinal disorders, etc. 

Listing 

Shares of Dr. Reddy's Laboratories are listed on BSE, NSE, Bangalore Stock Exchange, Calcutta Stock Exchange, etc. It is a part of multiple indices like Nifty 50, Nifty 500, S&P BSE 500 etc.